Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D. E. Furst, E. C. Keystone, B. Kirkham, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, G. R. Burmester, J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti, T. Dörner, A. Gibofsky, M. H. Schiff, J. Sieper, N. Singer, P. L.C.M. Van RielM. E. Weinblatt, M. H. Weisman

Research output: Contribution to journalArticle

102 Scopus citations

Abstract

Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

Original languageEnglish (US)
Pages (from-to)iii2-iii25
JournalAnnals of the rheumatic diseases
Volume67
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008'. Together they form a unique fingerprint.

  • Cite this

    Furst, D. E., Keystone, E. C., Kirkham, B., Fleischmann, R., Mease, P., Breedveld, F. C., Smolen, J. S., Kalden, J. R., Burmester, G. R., Braun, J., Emery, P., Winthrop, K., Bresnihan, B., De Benedetti, F., Dörner, T., Gibofsky, A., Schiff, M. H., Sieper, J., Singer, N., ... Weisman, M. H. (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the rheumatic diseases, 67(SUPPL. 3), iii2-iii25. https://doi.org/10.1136/ard.2008.100834